Ipca Laboratories Limited
IPCALAB
Rang în acțiuni
#3419
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Preț acțiune
$20.02
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$5.08B
Schimbare (1 zi)
-1.65%
Schimbare (1 an)
37.56%
Țară
IN
Tranzacționează Ipca Laboratories Limited (IPCALAB)
Categorie
Healthcare
Venituri pentru Ipca Laboratories Limited (IPCALAB)
Venituri în Jun 2026 TTM: $1.12B
Conform celor mai recente rapoarte financiare ale Ipca Laboratories Limited, venitul actual al companiei (TTM) este $1.12B. În anul 2024, compania a avut un venit de $924.15M o creștere față de venitul din anul 2023, care a fost de $760.29M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Ipca Laboratories Limited din 2005 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $1.12B | 6.89% |
| 2025 | $1.05B | 13.12% |
| 2024 | $924.15M | 21.55% |
| 2023 | $760.29M | -1.02% |
| 2022 | $768.09M | 3.73% |
| 2021 | $740.50M | 19.97% |
| 2020 | $617.22M | 13.54% |
| 2019 | $543.63M | 7.74% |
| 2018 | $504.56M | 3.67% |
| 2017 | $486.70M | 12.46% |
| 2016 | $432.77M | -14.12% |
| 2015 | $503.92M | -7.96% |
| 2014 | $547.51M | 5.75% |
| 2013 | $517.74M | 11.30% |
| 2012 | $465.16M | 9.12% |
| 2011 | $426.30M | 22.77% |
| 2010 | $347.24M | 37.32% |
| 2009 | $252.88M | -3.75% |
| 2008 | $262.72M | 21.27% |
| 2007 | $216.64M | 27.04% |
| 2006 | $170.53M | 9.66% |
| 2005 | $155.51M | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 491.67% |
IN
|
